Mutations in the genes encoding proteins constituting inflammasomes or regulating inflammasome activation cause IL-1β-mediated autoinflammatory diseases 1,2 . FMF and HIDS are two such disorders caused by missense mutations of MEFV and MVK, which encode pyrin and mevalonate kinase (MVK), respectively 3, 4 . Pyrin spontaneously forms an inflammasome, dependent on the adaptor ASC, when mutant 5 or in response to bacterial toxins 6 , and MVK is a key enzyme in the mevalonate pathway, producing isoprenoids 7 such as geranylgeranyl pyrophosphate. However, the exact molecular mechanism of pyrin inflammasome activation, as well as the molecular pathology of FMF and HIDS, is unknown.
A r t i c l e s Mutations in the genes encoding proteins constituting inflammasomes or regulating inflammasome activation cause IL-1β-mediated autoinflammatory diseases 1, 2 . FMF and HIDS are two such disorders caused by missense mutations of MEFV and MVK, which encode pyrin and mevalonate kinase (MVK), respectively 3, 4 . Pyrin spontaneously forms an inflammasome, dependent on the adaptor ASC, when mutant 5 or in response to bacterial toxins 6 , and MVK is a key enzyme in the mevalonate pathway, producing isoprenoids 7 such as geranylgeranyl pyrophosphate. However, the exact molecular mechanism of pyrin inflammasome activation, as well as the molecular pathology of FMF and HIDS, is unknown.
Published genetic studies of FMF in Sephardi Jewish families with severe disease revealed a recessive mode of inheritance 3, 8, 9 , suggesting that FMF might be caused by loss-of-function mutations in pyrin. However, the availability of genetic testing has led to both the definition of a biochemical phenotype in asymptomatic heterozygotes 10 and the recognition that as many as 30% of patients with clinical FMF have only a single demonstrable mutation in MEFV [11] [12] [13] . Indeed, several cases of apparently dominantly inherited FMF have been reported 14, 15 , whereas null mutations are extremely rare. Moreover, pyrin-deficient mice develop normally and exhibit no overt phenotype 5 , arguing against a loss-of-function model for FMF. Data from knock-in mice harboring FMF-associated mutations of the gene encoding human pyrin strongly support a gain-of-function model with a gene-dosage effect, with the mutant pyrin inducing an ASC-dependent inflammasome and IL-1β-mediated systemic inflammation 5 .
Certain bacterial toxins that inactivate Rho GTPases induce IL-1β production by the pyrin inflammasome through an indirect mechanism that does not involve an interaction between pyrin and Rho GTPases 6 . Our results elucidate a pathway by which RhoA activation induces downstream kinases, pyrin phosphorylation and the resulting inhibitory binding of phosphorylated pyrin by 14-3-3 proteins, and demonstrate the effects of pyrin and MVK mutations in relieving the tonic inhibition of the pyrin inflammasome. Bacterial sensing by pyrin therefore represents an example in which innate immunity in mammals is triggered by an indirect process that is similar to the 'guard' mechanism in plants 16, 17 .
RESULTS

RhoA activity suppresses pyrin inflammasome activation
Bacterial toxins that modify RhoA induce inflammasome formation by wild-type pyrin 6 . These bacterial toxins mediate the glucosylation, adenylylation, ADP-ribosylation or deamidation of various residues in the switch I region of RhoA, inhibiting guanine nucleotide binding and GTPase activity. Taken together with the absence of evidence for direct interaction between pyrin and modified RhoA 6 , the data suggest that the pyrin inflammasome is activated by the inhibition of downstream RhoA signaling pathways. Thus, we initially explored the correlation between RhoA activity and the pyrin inflammasome by studying bone-marrow-derived macrophages (BMDMs) in which pyrin had been induced by lipopolysaccharide (LPS) 18 .
Consistent with published findings 6 , the clostridial TcdB and C3 toxins induced caspase-1 activation and bioactive IL-1β release from LPS-primed BMDMs by a pathway that was dependent on pyrin, ASC and caspase-1 but independent of NLRP3, NLRC4 and AIM2 ( Fig. 1a and Supplementary Fig. 1a ). In contrast, C3-toxin-induced IL-1β release was substantially diminished when the BMDMs were treated with calpeptin, an indirect upstream RhoA activator 19 , or bacterial cytotoxic necrotizing factor (CNF) toxin, a direct RhoA activator that deamidates glutamine-63 of Rho 20,21 ( Fig. 1b and Supplementary Fig. 1b-d) .
RhoA activators also reduced IL-1β release from the LPS-primed BMDMs of FMF knock-in mice harboring the MEFV mutation encoding the V726A substitution (Mefv V726A/V726A ), in which the pyrin inflammasome is constitutively activated 5 ( Fig. 1c and Supplementary Fig. 1e ). On the other hand, the activation of RhoA had no suppressive effect on the NLRC4 or AIM2 inflammasomes ( Fig. 1d and Supplementary Fig. 1f ). The NLRP3 inflammasome was also not inhibited by the CNF toxin, despite its inhibition by calpeptin ( Fig. 1d and Supplementary Fig. 1f ).
Another line of evidence supporting the inverse relationship between RhoA activation and pyrin inflammasome induction follows from a published study of the inhibition of the NLRP3 inflammasome by intracellular cyclic AMP (cAMP), in which cAMP was found to accentuate IL-1β production by peripheral blood mononuclear cells (PBMCs) from patients with FMF 22 
of RhoA at Ser188 through protein kinase A (PKA), resulting in the translocation of membrane-associated RhoA toward the cytosol 23, 24 . The increase of cAMP synthesis by the adenylate cyclase (ADCY) activator NKH477 (a water-soluble analog of forskolin) potentiated IL-1β release from PBMCs of patients with FMF ( Supplementary  Fig. 2a ), whereas it moderately inhibited IL-1β release from PBMCs of patients with cryopyrin-associated periodic syndrome (CAPS) or ATP-treated wild-type mouse BMDMs (Supplementary Fig. 2b,c) . Indeed, we observed a dose-dependent decrease in RhoA-GTP activity and an increase in IL-1β release from the LPS-primed BMDMs of Mefv V726A/V726A mice in response to ADCY activation ( Fig. 1e) .
In conclusion, the data from both human and mouse leukocytes that were subjected to bacterial toxins and pharmacologic agents support the proposal of an inverse relationship between RhoA activity and pyrin inflammasome activation.
Colchicine suppresses the pyrin inflammasome
We next examined the effect of colchicine on the pyrin inflammasome, as colchicine is a known activator for RhoA and an effective prophylaxis for FMF inflammatory attacks. In the cytosol, colchicine binds to tubulin and depolymerizes microtubules, resulting in the release of the RhoA activator guanine-nucleotide-exchange factor (GEF)-H1, which is inactive when bound to microtubules 25 . Indeed, colchicine either activated RhoA or reversed the inhibition of RhoA activity by C3 toxin in LPS-primed BMDMs ( Fig. 2a) . Consistent with previous results showing an inverse relationship between RhoA activity and pyrin inflammasome activation, we observed that colchicine inhibited the constitutive IL-1β release from BMDMs of Mefv V726A/V726A mice and C3 toxin-induced IL-1β release from LPS-primed BMDMs (Fig. 2b,c) . In addition, we also observed inhibition of IL-1β release by colchicine from PBMCs of patients with FMF ( Fig. 2d) . In contrast, colchicine had no consistent dose-dependent inhibitory effect on NLRP3, NLRC4 or AIM2 inflammasome activation ( Fig. 2e) or the constitutive IL-1β release from the PBMCs of patients with CAPS ( Fig. 2f) , although it has been reported that colchicine inhibits NLRP3 inflammasome-induced IL-1β release at higher concentrations 26 . These data suggest an explanation for the exquisite specificity of colchicine for FMF among the monogenic autoinflammatory diseases.
RhoA effector kinases suppress pyrin inflammasome activation
Given that the pyrin inflammasome is activated by inactivation of RhoA, we hypothesized that a signaling pathway downstream of RhoA may suppress the pyrin inflammasome. A number of proteins have been identified as being effectors of RhoA, most notably kinases such as ROCKs and PKNs that belong to the protein kinase C (PKC) superfamily. It is noteworthy that staurosporine, a potent inhibitor of PKC and an inducer of cell death, stimulates IL-1β release from LPS-primed macrophages through an unknown inflammasome activation 27 . We found that staurosporine-induced IL-1β release was independent of the NLRP3, NLRC4 or AIM2 inflammasomes, but was dependent on the pyrin inflammasome ( Fig. 3a and Supplementary Fig. 3a ), suggesting that the pyrin inflammasome might be activated when a Rho effector kinase is inhibited.
To find RhoA effector kinases that regulate the pyrin inflammasome, we knocked down the genes encoding the Rho effector kinases PKNs and ROCKs in mouse BMDMs using small interfering RNA (siRNA). Knockdown of Pkn1 or Pkn2 in LPS-primed BMDMs npg A r t i c l e s induced spontaneous IL-1β release, which was dependent on the pyrin inflammasome, and this effect was accentuated when both Pkn1 and Pkn2 were knocked down (Fig. 3b,c) . However, knockdown of Rock1 or Rock2, or double knockdown of Rock1 and Rock2 did not induce IL-1β release (Fig. 3b) , indicating that ROCK1 and ROCK2 are dispensable for regulating the pyrin inflammasome. Furthermore, we also observed that the pyrin inflammasome was activated in LPS-primed BMDMs by PKC412, a potent inhibitor of PKNs 28 (Fig. 4a) . Conversely, IL-1β release from BMDMs treated with C3 toxin or from BMDMs of Mefv V726A/V726A mice was markedly inhibited by bryostatin 1, a potent PKC activator ( Fig. 4b and Supplementary Fig. 3b ). In contrast, NLRP3 inflammasome activation induced by ATP, AIM2 inflammasome activation induced by double-stranded DNA and NLRC4 inflammasome activation induced by flagellin were not suppressed by bryostatin 1 (Supplementary  Fig. 3c ). The activation of the pyrin inflammasome was also suppressed by arachidonic acid, a known activator of both PKNs and ROCKs 29, 30 (Fig. 4c and Supplementary Fig. 3d ). The effects of arachidonic acid are not as inflammasome-selective as those of bryostatin 1, as arachidonic acid suppressed ATP-driven NLRP3 inflammasome activation through its effects on cAMP 22, 31, 32 , although it did not suppress the IL-1β release induced by NLRC4 or AIM2 inflammasome IB: V5 (PKN1) Figure 6 The binding of PKN1 to the pyrin of FMF knock-in mice is substantially less than its binding to wild-type mouse pyrin, which lacks a B30.2 orthologous domain, and knockin mice with the wild-type B30.2 domain of human pyrin have a milder inflammatory phenotype than that of knock-in mice with FMF-associated mutations. (a) Immunoblot analysis of PKN1 and pyrin in LPS-treated BMDMs from wild-type and FMF knock-in (FMF-KI) with wild-type human B30.2 domain or various FMF-associated mutant human B30.2 domains (above lanes), assessed before (Lys) or after (IP) immunoprecipitation with antibody to pyrin. Below, densitometry analysis of PKN1 bands, normalized to pyrin bands. (Supplementary Fig. 3e) . Consistent with the results of the aforementioned siRNA experiments, the constitutive IL-1β release from PBMCs of patients with FMF was substantially decreased by both PKN activators bryostatin 1 and arachidonic acid ( Fig. 4d,e ). Taken together, these genetic and pharmacological data from murine and human experimental systems support the proposal of a role for PKN enzymes in suppressing the pyrin inflammasome.
PKNs bind to human pyrin and phosphorylate Ser208 and Ser242
To understand how PKNs suppress pyrin inflammasome activation, we tested whether pyrin is a substrate of PKNs. In a co-immunoprecipitation assay, we found an interaction of endogenous pyrin with PKN1 in lysates of LPS-primed BMDMs (Fig. 5a) . The pyrin-PKN1 interaction was decreased by C3 toxin, but the decreased interaction was restored by co-treatment with arachidonic acid or bryostatin 1 (Fig. 5a) , indicating that activated PKN1 binds to pyrin and dissociates when PKN1 is inactivated. PKN1 is a serine-threonine protein kinase that has a catalytic kinase domain at its C terminus and an N-terminal regulatory region where activated RhoA and arachidonic acid bind. Human PKN1 interacts with pyrin through this C-terminal kinase domain ( Fig. 5b) , suggesting that pyrin might be phosphorylated. Indeed, direct phosphorylation of pyrin by PKN1 and PKN2 was observed from an incubation of the purified N-terminal half of human pyrin with recombinant PKN1 or PKN2 and subsequent staining of phosphorylated proteins or immunoblot analysis with an antibody to phosphorylated serine (Fig. 5c) .
We also examined the binding of PKN1 to pyrin in FMF knock-in mice. Most FMF-associated mutations are in sequence encoding the C-terminal B30.2 domain of human pyrin, a domain that is not present in mouse pyrin. We found that the binding of PKN1 to the pyrin of FMF knock-in mice with three frequent FMF-associated B30.2 mutations (Mefv M680I/M680I , Mefv M694V/M694V and Mefv V726A/V726A ) was substantially decreased relative the binding of PKN1 to wild-type (Mefv +/+ ) mouse pyrin, which lacks a B30.2 orthologous domain (Fig. 6a) . The binding of PKN1 to the pyrin of wild-type B30.2 domain knock-in mice (Mefv B30.2/B30.2 ) was also decreased relative to its binding to wild-type mouse pyrin, but was not decreased by as much as it was with the pyrin proteins from Mefv M694V/M694V or Mefv V726A/V726A mice. Mefv B30.2/B30.2 mice have been thought to die in utero 5 , but we have succeeded in breeding these animals. These mice showed spontaneous inflammatory phenotypes, but the severity as well as IL-1β release from LPS-primed leukocytes was much lower than that of Mefv V726A/V726A mice, which show the most severe inflammation 5 (Fig. 6b-d and Supplementary Fig. 4a,b) . These findings suggest that the human B30.2 domain has a role in the regulation of PKN1 binding to pyrin.
14-3-3 binds phosphopyrin to inhibit inflammasome activation
Serine residues at positions 208, 209 and 242 of human pyrin have been reported to be phosphorylated and to mediate the interaction with two isoforms of 14-3-3 proteins 33 . We found that Ser208 and Ser242 of human pyrin are phosphorylated by PKN1 or PKN2 (Fig. 7a ) LPS Lys IP: pyrin 14-3-3ε
14-3-3ε
Pro-IL-1β A r t i c l e s and that 14-3-3ε or 14-3-3τ bind to the N-terminal portion of pyrin through Ser208 and Ser242 but not Ser209 ( Supplementary  Fig. 5a,b) . Consistent with the C3-toxin-induced attenuation of the PKN1-pyrin interaction (Fig. 5a) , the 14-3-3ε-pyrin interaction was substantially decreased by C3 toxin, an effect that was reversed by PKN activators (Fig. 7b) .
The binding of 14-3-3ε to mouse pyrin from the FMF knock-in mice was substantially diminished relative to binding to pyrin from wild-type mice ( Fig. 7c and Supplementary Fig. 5c ), which was also consistent with the PKN1-pyrin interaction (Fig. 6a) . In the lysates of BMDMs from Mefv V726A/V726A mice, the 14-3-3ε-pyrin interaction was increased by either PKN activation with arachidonic acid or bryostatin 1, or RhoA activation by colchicine ( Supplementary  Fig. 5d,e) . Furthermore, the binding of 14-3-3ε to disease-associated mutant pyrin (M680I, M694V and V726A) was substantially decreased relative to binding to wild-type human pyrin in ectopically expressing 293T cells and macrophages differentiated from the PBMCs of patients with FMF ( Fig. 7d,e) .
Together with the inhibition of IL-1β release from BMDMs of Mefv V726A/V726A mice (Fig. 4b,c) or PBMCs of patients with FMF ( Fig. 4d,e ) by PKN activation, these findings suggest that the spontaneous activation of the inflammasome in myeloid cells of FMF knockin mice or patients with FMF might be a result of reduced suppression of pyrin activation by 14-3-3 proteins. Consistent with this hypothesis, spontaneous pyrin-dependent IL-1β release was observed in BMDMs following knockdown of both 14-3-3ε and 14-3-3τ (Fig. 7f) . Moreover, ectopic expression of the Ser208A or Ser242A pyrin mutants, which do not interact with 14-3-3, induced IL-1β release in U937 cells without upstream pyrin inflammasome activators, whereas only basal levels of IL-1β were secreted by the non-transfected cells or those expressing wild-type pyrin (Fig. 7g) . The binding of 14-3-3 to phosphorylated pyrin therefore acts as a molecular switch to turn off pyrin inflammasome activation that would otherwise occur when either 14-3-3 expression or pyrin serine phosphorylation is blocked by bacterial toxins, FMF-associated B30.2 mutations or pharmacologic agents ( Supplementary Figs. 6 and 7) .
The pyrin inflammasome mediates IL-1β release in HIDS In addition to the GEF-mediated exchange of GDP with GTP on RhoA, the translocation of RhoA from the cytosol to the plasma membrane is essential for its biological function. Membrane targeting of RhoA is dependent on geranylgeranylation at its C terminus. Geranylgeranyl pyrophosphate, the substrate of geranylgeranylation, is a product of the mevalonate pathway. HIDS is caused by loss-of-function mutations in the gene encoding MVK. The deficiency in MVK function observed in HIDS, or the pharmacological inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, results in the depletion of geranylgeranyl pyrophosphate, which has been reported to induce IL-1β release in myeloid cells through an unknown inflammasome [34] [35] [36] . Given that RhoA is inactive without geranylgeranylation and that the inactivation of RhoA induces pyrin inflammasome activation, we investigated the role of pyrin in the pathogenesis of HIDS.
Simvastatin, a direct inhibitor of HMG-CoA reductase, induced translocation of RhoA from the membrane to the cytosol and a dose-dependent release of IL-1β from LPS-primed BMDMs (Supplementary Fig. 8a,b) . The IL-1β release induced by various HMG-CoA reductase inhibitors-simvastatin, fluvastatin and lovastatin-was dependent on the pyrin inflammasome, but was independent of the NLRP3, NLRC4 or AIM2 inflammasomes ( Fig. 8a  and Supplementary Fig. 8b-d) . We also found that the IL-1β release induced by simvastatin was blocked by supplementation with geranylgeranyl pyrophosphate or activation of PKNs with arachidonic acid or bryostatin 1, which suppress the pyrin inflammasome (Fig. 8b,c and Supplementary Fig. 8e-g) .
As seen in cells treated with C3 toxin, simvastatin also substantially decreased the 14-3-3ε-pyrin interaction, as well as the PKN1-pyrin interaction in LPS-primed BMDMs, and these decreased interactions were reversed by the activation of PKNs or by supplementation with npg A r t i c l e s exogenous geranylgeranyl pyrophosphate ( Fig. 8d-g) . These data indicate that a blockade of the mevalonate pathway induces pyrin inflammasome activation. Of note, the HMG-CoA reductase inhibitor concentrations required to achieve such a blockade were much higher than the blood levels achieved in patients treated with these agents for hypercholesterolemia. Consistent with the data above, the constitutive IL-1β release from PBMCs of patients with HIDS was substantially blocked by the suppression of the pyrin inflammasome with arachidonic acid or bryostatin 1 (Fig. 8h,i) . Unlike the results obtained for FMF, however, we found little or no inhibitory effect of colchicine on pyrin inflammasome activation in PBMCs of patients with HIDS ( Supplementary  Fig. 8h ), most probably because colchicine could not activate RhoA that was not localized to the cell membrane through geranylgeranylation. These findings indicate an essential role for the pyrin inflammasome in the pathogenesis of HIDS and also provide an 'experiment of nature' demonstrating the activation of the pyrin inflammasome by inhibiting the RhoA signaling pathway (Supplementary Fig. 6 ).
DISCUSSION
By studying RhoA signal transduction, we determined how bacterial toxins activate the pyrin inflammasome. Our central finding, that the pyrin inflammasome is regulated by RhoA-dependent phosphorylation of pyrin and pyrin's subsequent interaction with 14-3-3 proteins, also delineates the molecular pathogenesis of FMF and defines a previously unknown connection between FMF and the seemingly unrelated autoinflammatory disease HIDS. Our data are consistent with the emerging concept that FMF mutations are gainof-function with a gene-dosage effect 5 , and the existence of rare FMF mutations at both phosphorylated serine residues of pyrin provides direct evidence of a role for the 14-3-3 proteins in FMF (http://fmf. igh.cnrs.fr/ISSAID/infevers/). This concept is strengthened by the description of a previously unnkown, dominantly inherited disorder known as 'pyrin-associated autoinflammation and neutrophilic dermatosis' , which is caused by the pSer242Arg mutation in pyrin 37 .
Most of the more common and severe FMF-associated mutations are clustered in the C-terminal B30.2 domain of human pyrin. Perhaps as a result of intramolecular interactions, B30.2 domain mutations are likely to control pyrin phosphorylation by inhibiting the binding of kinases to pyrin. Thus, we hypothesize that FMFassociated mutations in the B30.2 domain block the phosphorylation sites from kinases, such as PKN1, resulting in a lowered threshold for activation of the pyrin inflammasome. In mice, which lack a pyrin B30.2 domain, one would expect that the balance would favor the phosphorylated, inhibited state, unless the mouse has evolved phosphatases that tip the balance toward the dephosphorylated, activated state.
Given the extraordinarily high carrier frequency of FMF-associated MEFV mutations in Mediterranean and Middle Eastern populations, the possibility that heterozygous FMF mutations might confer a selective advantage against one or more pathogenic microbes has long been a topic of intense interest. Our findings provide a molecular account of how this may have happened: bacterial toxins that inactivate RhoA have been evolutionarily selected in bacteria because they disable host cell cytoskeletal organization and the numerous downstream hostdefense mechanisms, such as leukocyte migration and phagocytosis, that depend on an intact cytoskeleton. The pyrin inflammasome is probably a host counter-measure that resembles the plant guard-type mechanism, allowing hosts to defend against a wide range of pathogens by sensing particular virulence-related activities rather than by sensing pathogen-associated molecular patterns directly 17, 38 .
This hypothesis proposes that the pyrin inflammasome can control a broad spectrum of potential pathogenic infections, perhaps broader than currently appreciated. Normal pyrin exerts its role by nucleating an inflammasome to defend against bacteria, such as Clostridium difficile, Burkholderia cenocepacia and Vibrio cholerae, which utilize toxins to inactivate Rho GTPase, thereby inducing actin depolymerization. The adenylate cyclase toxins secreted from Bordetella pertussis, Bacillus anthracis, Pseudomonas aeruginosa and Yersinia pestis induce intracellular accumulation of cAMP in the host cell 39 . Although the increase of cAMP suppresses the NLRP3 inflammasome 22 , it conversely potentiates pyrin inflammasome activation. Thus, pyrin may function as an innate immune 'guard' in much the same way that R proteins function in plant antimicrobial defense. The requirement for both a priming step and RhoA inactivation prevents pyrin inflammasome activation from being triggered by normal cellular processes. However, the end result is a potent mechanism that defends against a major class of pathogens, and the double-edged sword that is genetic variation in this system of defense.
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